Opinion|Videos|March 13, 2025
Applying Results From PEACE-3 to Your Patient Population
Panelists discuss how adapting the PEACE-3 protocol to real-world US patient populations requires careful consideration of broader patient demographics, comorbidities, and prior treatment histories than were represented in the trial’s relatively strict eligibility criteria.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- The eligibility criteria of the PEACE-3 trial are different from the patient demographics we see here in the US; how would you go about applying the PEACE-3 protocol to your patient population?
- How do the PEACE-3 trial results compare with current first-line treatment options for metastatic castration-resistant prostate cancer?
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Alan Bryce, MD, highlights key phase 3 advances in prostate cancer
2
FDA clears Revi Extend implant for urgency urinary incontinence
3
FDA updates in urology: July 2026
4
FDA grants tentative approval to new cabozantinib capsule formulation
5